Useful Insights from LUGPA Benchmarks:
Tracking Underwater Drugs

Oct. 2021

Monitoring net cost recovery is imperative to the success of buy and bill services.  A recent finding from the LUGPA Benchmarking Program found that a large national payer was limiting the amount of billable units paid for Firmagon (J9155 - degarelix) for the initial loading dose.  This on average yielded a $577 net cost recovery loss on the initial administration. 

Practices participating the LUGPA benchmarking program can contact [email protected] to receive information specific to your practice.

To learn more about how to monitor net cost recovery on your buy and bill services, contact Kathy Stack – [email protected].